Huashen Zhiyao completed nearly 500million yuan of round a financing and continued to develop new AI drugs

Recently, helixon announced that it had completed nearly 500million yuan of round a financing. This round of financing is led by Wuyuan capital, followed by Gaorong capital, Neumann capital and three Angel round investors Xianghe capital, Hillhouse venture capital and Qingzhi capital. Huashen Zhiyao will continue to work in the field of ai+ new drug development, expand team and business development, improve AI's high-performance computing capabilities, expand high-throughput experimental platforms, and promote pipeline independent research and development and foreign cooperation. Huashen Zhiyao is committed to building the next generation of artificial intelligence scientific computing platform. Combined with self-developed high-throughput biological experimental technology, it provides drug R & D personnel with an intelligent system for micro world molecular computing, simulation and design. In the field of new drug development, especially macromolecular drug discovery, Huashen Zhiyao is innovatively developing efficient machine learning algorithms and data acquisition technologies to reconstruct the drug development process, so as to greatly improve the speed and efficiency of new drug development. Dr. PENGJian, the founder of Huashen Zhiyao, said, "thank Wuyuan capital, Gaorong capital, Neumann capital and the old shareholders for their full support. This financing once again proves that the market highly recognizes the technology and business development of Huashen Zhiyao. We will unswervingly move forward quickly, increase R & D investment, fully promote cooperation and pipeline development, and protect human health with artificial intelligence."